These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 8431510)
21. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation. Capucha V; Mendes E; Francisco AP; Perry MJ Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157 [TBL] [Abstract][Full Text] [Related]
22. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451 [TBL] [Abstract][Full Text] [Related]
23. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695 [TBL] [Abstract][Full Text] [Related]
24. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849 [TBL] [Abstract][Full Text] [Related]
25. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406 [TBL] [Abstract][Full Text] [Related]
26. Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Sharma SK; Bagshawe KD; Melton RG; Begent RH Transplant Proc; 1996 Dec; 28(6):3154-5. PubMed ID: 8962222 [No Abstract] [Full Text] [Related]
27. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study. Springer CJ; Poon GK; Sharma SK; Bagshawe KD Cell Biophys; 1993; 22(1-3):9-26. PubMed ID: 7889545 [TBL] [Abstract][Full Text] [Related]
29. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666 [TBL] [Abstract][Full Text] [Related]
30. Enzyme and proton-activated prodrugs for a selective cancer therapy. Tietze LF; Feuerstein T Curr Pharm Des; 2003; 9(26):2155-75. PubMed ID: 14529411 [TBL] [Abstract][Full Text] [Related]
31. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Tietze LF; Schmuck K Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425 [TBL] [Abstract][Full Text] [Related]
32. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Jung M Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965 [TBL] [Abstract][Full Text] [Related]
33. Antitumor effects of antibody enzyme conjugates in combination with prodrugs. Senter PD Front Radiat Ther Oncol; 1990; 24():132-41; discussion 161-5. PubMed ID: 2341048 [No Abstract] [Full Text] [Related]